Retrospective post-marketing surveillance of Transiderm-Nitro 5 in general practice in the United Kingdom.
A retrospective post-marketing surveillance of Transiderm-Nitro 5 was undertaken in 1803 general practice patients with various degrees of severity of angina. Over half the patients were assessed more than 3 months after starting treatment. At the time of assessment two-thirds of the patients were continuing with their Transiderm-Nitro therapy. Only a small proportion (3.8%) of the total patient population were withdrawn after 3 months' usage. This suggests the continuing benefit of longer term Transiderm-Nitro therapy. Subjective assessment of a reduction in the number of anginal attacks and an improvement in exercise capacity occurred, respectively, in 76.2% and 62.6% of the patients. Although 16% of patients experienced problems specifically related to patch use, only 6.4% withdrew for these reasons. The incidence of headache decreased with time of usage of Transiderm-Nitro to give an over-all withdrawal of 7%. The death rate observed during the surveillance lies between that for the United Kingdom population as a whole and that for a population with angina pectoris. This surveillance shows that both patients and doctors perceived clinical benefit from Transiderm-Nitro when used in the treatment of angina.
D000287:Administration, Topical; D000328:Adult; D000368:Aged; D000787:Angina Pectoris / Q000188:drug therapy* / Q000503:physiopathology; D002118:Calcium / Q000037:antagonists & inhibitors; D004359:Drug Therapy, Combination; D005194:Family Practice; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009566:Nitrates / Q000627:therapeutic use; D005996:Nitroglycerin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012189:Retrospective Studies; D013997:Time Factors
D009566:Nitrates; D005996:Nitroglycerin; D002118:Calcium